Heska completes acquisition of LightDeck diagnostics

Heska a global provider of advanced veterinary diagnostic and specialty products and solutions, announced the completion of acquisition of 100% of the shares of MBio Diagnostics, d/b/a LightDeck Diagnostics (“LightDeck”), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the “Acquisition”).

The Acquisition, which was first announced on September 12, 2022 , represents a key advancement in the Company’s strategic plan to accelerate research and development and manufacturing capabilities at scale. Founded in 2009 in Boulder, Colorado , LightDeck has developed a scalable and innovative platform based on an extensive intellectual property for rapid and accurate point of care diagnostics. LightDeck’s planar waveguide technology optimizes laser activated fluorescence and microfluidics to produce point of care cartridge-based testing for quantitative results in minutes with inexpensive, easy-to-use workflow. LightDeck’s facilities include fully equipped laboratories for assay development, controlled manufacturing capabilities, and a new, state-of-the-art, fully automated facility in Longmont, Colorado that will further advance in-clinic testing manufacturing at scale. The Longmont facility, anticipated to go online in 2023, will dramatically increase Heska’s manufacturing production capacity and research and development efforts in furtherance of several potential blockbuster testing platforms, including the Company’s exclusive canine cancer screening platform anticipated to launch in 2023.

Heska management expects to comment further on the Acquisition and provide additional details in the Company’s fourth quarter and full year 2022 financial earnings release and conference call late February 2022 .